RECRUITING

Partners Calciphylaxis Biobank

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles. There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis. The Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.

Official Title

Partners Calciphylaxis Biobank and Patient Registry

Quick Facts

Study Start:2017-01
Study Completion:2030-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03032835

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Male or female ≥18 years old
  2. 2. Skin lesions consistent with calciphylaxis diagnosis as determined by the treating clinician
  3. 3. Informed of the investigational nature of the study and sign written Informed consent OR are eligible for surrogate consent process based on impaired decision making
  1. 1. Patients \<18 years of age
  2. 2. Prisoners

Contacts and Locations

Study Contact

Sagar U Nigwekar, MD, MMSc
CONTACT
617-726-7872
snigwekar@mgh.harvard.edu

Principal Investigator

Sagar U Nigwekar, MD, MMSc
PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital

Study Locations (Sites)

Massachusetts General Hospital
Boston, Massachusetts, 02114
United States

Collaborators and Investigators

Sponsor: Massachusetts General Hospital

  • Sagar U Nigwekar, MD, MMSc, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-01
Study Completion Date2030-12

Study Record Updates

Study Start Date2017-01
Study Completion Date2030-12

Terms related to this study

Keywords Provided by Researchers

  • Calciphylaxis
  • Warfarin
  • Dialysis

Additional Relevant MeSH Terms

  • Calciphylaxis
  • Calcific Uremic Arteriolopathy
  • End Stage Renal Disease
  • Chronic Kidney Diseases